Research presented Wednesday at the 2014 International Alzheimer's Association International Conference shows that a new drug may help slow early stages of the disease.
Scientists followed more than 400 patients with mild-to-moderate Alzheimer's disease for 73 weeks. Some patients were given a high dose of the drug, crenezumab, intravenously every four weeks. Others received a low dose injection of the drug under the skin every other week. And the rest were given a placebo.
Researchers say in milder forms of the disease, the high-dose IV form of the drug did show evidence of slowing the decline of cognitive abilities.
Copyright 2015 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.